Samuel Z. Goldhaber, MD, Professor of Medicine at Harvard Medical School, is the Interim Chief of  the division of Cardiovascular Medicine and Section Head of the Vascular Medicine Division at Brigham and Women’s Hospital (BWH). He is Director of the BWH Thrombosis Research Group, medical co-director of the BWH Anticoagulation Management Service, and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of pulmonary embolism, deep vein thrombosis, stroke prevention in atrial fibrillation, and prevention of recurrent myocardial infarction.

Dr. Goldhaber is President and a Founding Director of the North American Thrombosis Forum. For his work on prevention of venous thromboembolism, Dr. Goldhaber has received the Certificate of Appreciation from the Surgeon General of the United States.

He chairs the Steering Committee of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored ATTRACT Trial of DVT treatment. Dr. Goldhaber is a member of the Steering Committee and is the U.S. National Coordinator of the GARFIELD Atrial Fibrillation cohort study and the GARFIELD Venous Thromboembolism cohort study. He is a Section Editor for Circulation and for Thrombosis and Haemostasis. He also has a busy practice of general cardiology, venous thromboembolism, and atrial fibrillation patients.